Comparative effects of pharmacotherapy on the maintenance of cognitive function

• Published in: European psychiatry Vol. 16; no. S1; pp. 35 - 41
• Main Authors: Allain, H, Schück, S, Mauduit, N, Djemai, M
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Paris Elsevier SAS 2001; Elsevier
• Subjects: Alzheimer Disease - complications; antipsychotics; Biological and medical sciences; clinical trials; Clinical Trials as Topic; cognition; Cognition - drug effects; Cognition Disorders - complications; Cognition Disorders - drug therapy; dementia; Humans; Medical sciences; memory; Memory - drug effects; Neuropharmacology; Pharmacology. Drug treatments; pharmacovigilance; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Psychotropic Drugs - pharmacology; Psychotropic Drugs - therapeutic use; Quality of Life; antipsychotics; dementia; clinical trials; memory; cognition; pharmacovigilance; Agitation; Neuroleptic; Psychotropic; Memory; Cognition; Review; Behavioral disorder; Cognitive map; Medical prescription; Degenerative disease; Human; Vigilance; Nervous system diseases; Decision making; Violence; Attention; Cerebral disorder; Senile dementia; Symptomatology; Chemotherapy; Clinical management; Treatment; Central nervous system disease; Typology; Elderly; Comparative study
• ISSN: 0924-9338; 1778-3585
• DOI: 10.1016/S0924-9338(00)00528-9

The quality of human cognitive performance appears today as one of the main components of quality of life, whatever the age. Ageing by itself and most of the diseases affecting the central nervous system alter higher brain functions such as memory, vigilance and attention. Dementia is the most acute example, with a cascade of behavioral and psychological consequences (BPSD), which are the main cause of the caregiver’s burden and need specific pharmacotherapy. In this respect, the problem will be the choice of the best drug in situations such as wandering, agitation, violence, and screaming. The psychotropics, however, should not deteriorate the already disturbed cognition of the patients. This is the reason why we propose to establish for each drug, and notably for the antipsychotics, a precise and exact ‘cognitive mapping’; in other words, to measure the effects of drugs on the different components of cognition. The results of such studies will be predictive of the future phase III clinical trials and therapeutic responses. As an illustration of this approach we shall relate two studies, TIATEM (phase I) and TIAGE (phase III/IV), leading to the determination of a good cognitive safety profile of an atypical neuroleptic drug, tiapride.